A085660 Stock Overview
CHA Biotech Co., Ltd., together with its subsidiaries, engages in cell therapy development, cord blood, and stem cell banking services.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
CHA Biotech Co., Ltd. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | ₩15,410.00 |
52 Week High | ₩18,250.00 |
52 Week Low | ₩11,930.00 |
Beta | 0.53 |
1 Month Change | 16.48% |
3 Month Change | 8.75% |
1 Year Change | -14.15% |
3 Year Change | -31.21% |
5 Year Change | -18.03% |
Change since IPO | 106.47% |
Recent News & Updates
Shareholder Returns
A085660 | KR Healthcare | KR Market | |
---|---|---|---|
7D | 3.4% | 3.9% | 1.8% |
1Y | -14.2% | 16.9% | -2.3% |
Return vs Industry: A085660 underperformed the KR Healthcare industry which returned 16.9% over the past year.
Return vs Market: A085660 underperformed the KR Market which returned -2.5% over the past year.
Price Volatility
A085660 volatility | |
---|---|
A085660 Average Weekly Movement | 4.6% |
Healthcare Industry Average Movement | 6.2% |
Market Average Movement | 5.7% |
10% most volatile stocks in KR Market | 12.3% |
10% least volatile stocks in KR Market | 2.9% |
Stable Share Price: A085660 is not significantly more volatile than the rest of KR stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: A085660's weekly volatility (5%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2002 | 266 | Hoon Oh Sang | https://www.chabio.com |
CHA Biotech Co., Ltd., together with its subsidiaries, engages in cell therapy development, cord blood, and stem cell banking services. The company operates a cord blood consignment storage business for the treatment of intractable diseases, as well as provides regenerative medicines, Immune and stem cell storage services, anti-aging, and solutions for incurable diseases; medical wellness programs comprising fitness, spa, and supplements; and customized development, production, clinical, and commercialization services to customers with research and development, and clinical experience. It also offers optimized IT system construction and operation; consulting services for development, operation, and expansion of Chaum model; and solutions for maternal-centered genome testing and personalized healthcare.
CHA Biotech Co., Ltd. Fundamentals Summary
A085660 fundamental statistics | |
---|---|
Market Cap | ₩845.68b |
Earnings (TTM) | -₩37.04b |
Revenue (TTM) | ₩892.98b |
0.9x
P/S Ratio-22.8x
P/E RatioIs A085660 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
A085660 income statement (TTM) | |
---|---|
Revenue | ₩892.98b |
Cost of Revenue | ₩666.25b |
Gross Profit | ₩226.73b |
Other Expenses | ₩263.77b |
Earnings | -₩37.04b |
Last Reported Earnings
Mar 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -674.89 |
Gross Margin | 25.39% |
Net Profit Margin | -4.15% |
Debt/Equity Ratio | 59.9% |
How did A085660 perform over the long term?
See historical performance and comparison